Publication

Preclinical molecular imaging to study the biodistribution of antibody derivatives in oncology

Warnders, J. F., 2018, [Groningen]: Rijksuniversiteit Groningen. 191 p.

Research output: ThesisThesis fully internal (DIV)Academic

Copy link to clipboard

Documents

  • Title and contents

    Final publisher's version, 111 KB, PDF document

  • Chapter 1

    Final publisher's version, 763 KB, PDF document

  • Chapter 2

    Final publisher's version, 1 MB, PDF document

  • Chapter 3

    Final publisher's version, 1 MB, PDF document

  • Chapter 4

    Final publisher's version, 1 MB, PDF document

  • Chapter 5

    Final publisher's version, 4 MB, PDF document

  • Chapter 6

    Final publisher's version, 4 MB, PDF document

  • Chapter 7

    Final publisher's version, 336 KB, PDF document

  • Chapter 8

    Final publisher's version, 348 KB, PDF document

  • Chapter 9

    Final publisher's version, 335 KB, PDF document

  • Dankwoord

    Final publisher's version, 73 KB, PDF document

  • About the author

    Final publisher's version, 64 KB, PDF document

  • Complete thesis

    Final publisher's version, 13 MB, PDF document

  • Propositions

    Final publisher's version, 47 KB, PDF document

  • Jan Feije Warnders
The successful use of antibodies for the treatment of cancer has spurred the interest in the development of antibody derivatives, such as Bispecific T-cell engagers (BiTEs) and nanobody constructs. Molecular imaging may facilitate drug development of BiTEs and nanobody constructs and decision making throughout this process. By radiolabeling antibody derivatives with zirconium-89 (89Zr), their pharmacokinetic profile, organ distribution and tumor uptake can be studied non-invasively by 89Zr-PET. In addition, fluorescent labeling of antibody derivatives enables studying their distribution within tumors, at a microscopic level. Furthermore, injecting fluorescently labeled nanobodies, that target tumor tissue, may facilitate real-time visualization of tumors in an intraoperative setting.
Given the overexpression on a variety of tumor cells, EpCAM, CEA and HER3 are interesting targets for BiTEs and nanobodies. In order to facilitate their drug development, an anti-EpCAM BiTE, anti-CEA BiTE and anti-HER3 nanobody construct have been radiolabeled with 89Zr. 89Zr-PET was used to study their organ distribution and tumor uptake. Radiolabeling of the anti-CEA BiTE was additionally used to study its in vivo integrity in serum and tumors. The obtained preclinical data have been used to setup a clinical trial, in which 89Zr-PET is used to study organ distribution and tumor uptake of this anti-CEA BiTE in cancer patients.
This thesis also describes the selection and preclinical evaluation of anti-HER2 nanobodies, fluorescently labeled with IRDye 800CW. Shortly after injection, the best performing nanobody enabled tumor visualization of HER2-positive tumors using optical imaging. It accumulated quicker in these tumors than 800CW-trastuzumab, a fluorescently labeled anti-HER2 drug.
Original languageEnglish
QualificationDoctor of Philosophy
Awarding Institution
Supervisors/Advisors
Award date4-Jul-2018
Place of Publication[Groningen]
Publisher
Publication statusPublished - 2018

Download statistics

No data available

ID: 61780808